WO2011070499A1 - Biomarqueurs de la voie de la phosphatidylinotisol-3-kinase - Google Patents

Biomarqueurs de la voie de la phosphatidylinotisol-3-kinase Download PDF

Info

Publication number
WO2011070499A1
WO2011070499A1 PCT/IB2010/055604 IB2010055604W WO2011070499A1 WO 2011070499 A1 WO2011070499 A1 WO 2011070499A1 IB 2010055604 W IB2010055604 W IB 2010055604W WO 2011070499 A1 WO2011070499 A1 WO 2011070499A1
Authority
WO
WIPO (PCT)
Prior art keywords
pik3ca
pten
subject
mutation
pi3k
Prior art date
Application number
PCT/IB2010/055604
Other languages
English (en)
Inventor
Anna Berkenblit
Christina Marie Coughlin
Jay Marshall Feingold
Daniel Stephen Johnston
Andrew Louis Strahs
Charles Michael Zacharchuk
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Priority to US13/514,556 priority Critical patent/US20130189274A1/en
Priority to CA2783743A priority patent/CA2783743C/fr
Priority to EP19170821.3A priority patent/EP3575413A1/fr
Priority to EP10805335A priority patent/EP2510121A1/fr
Publication of WO2011070499A1 publication Critical patent/WO2011070499A1/fr
Priority to US15/099,429 priority patent/US20160222467A1/en
Priority to US16/416,083 priority patent/US20190271047A1/en
Priority to US17/522,637 priority patent/US20220170107A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Definitions

  • the present disclosure relates to methods for treating breast cancer.
  • the cancer may be resistant to treatment with one or more known breast cancer treatment drugs.
  • the present disclosure also provides a patient selection strategy (i.e., identify patients with "PI3K activated" tumors) for predicting patient response to drug therapy.
  • the disclosure is also related to methods of treating breast cancer patients with a pan-ErbB tyrosine kinase inhibitor.
  • Constitutive PI3K activation in human cancer is thought to contribute to drug resistance to targeted agents and standard cytotoxic therapy.
  • the combination of activation mechanisms and the multiple downstream cascades that emanate from the PI3K node contribute to the difficulty in measuring PI3K activation as a biomarker.
  • Neratinib is an orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity.
  • Neratinib binds to the HER-2 receptor irreversibly, thereby reducing autophosphorylation in cells, apparently by targeting a cysteine residue in the ATP- binding pocket of the receptor.
  • Treatment of cells with this agent results in inhibition of downstream signal transduction events and cell cycle regulatory pathways; arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle; and ultimately decreased cellular proliferation.
  • Neratinib also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.
  • EGFR epidermal growth factor receptor
  • Trastuzumab (Herceptin) is a monoclonal antibody that interferes with the HER2/Neu HER2/neu receptor.
  • the HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off.
  • the HER proteins regulate cell growth, survival, adhesion, migration, and differentiation— functions that are amplified or weakened in cancer cells.
  • the HER2 receptor is defective and stuck in the "on" position, and causes breast cells to reproduce uncontrollably, causing breast cancer.
  • the invention provides methods for treating breast cancer in a subject which comprise obtaining a sample from the subject; detecting the presence or absence of one or more of PIK3CA gene amplification; a mutation in PIK3CA; and a decrease in PTEN protein expression; and treating a patient that is positive for the presence of one or more of PIK3CA gene amplification; a mutation in PIK3CA; and a decrease in PTEN protein expression by administering a pan-ErbB tyrosine kinase inhibitor.
  • the pan-ErbB inhibitor is irreversible and prevents binding of PIK3CA to the intracellular portion of the ErbB receptor and in some embodiments the intracellular inhibitor of ErbB receptor tyrosine kinases is neratinib.
  • the invention provides methods of treatment as described herein where the mutation in the PIK3CA gene comprises one or more of the following point mutations: in exon 9 E is substituted with K at position 542 of the mature protein sequence; E with K or D at amino acid 545; and in exon 20 H is substituted with R at amino acid 1047 of the mature protein sequence.
  • detection of the mutation in the PIK3CA gene comprises a Polymerase Chain Reaction (PCR) assay, or direct nucleic acid sequencing or hybridization with a nucleic acid probe specific for the PIK3CA gene.
  • the detection of PTEN expression comprises one or more of: reverse phase protein array, western blotting, semi-quantitative or quantitative IHC.
  • the invention provides methods for treating breast cancer in a subject which comprise obtaining a sample from the subject; detecting the presence or absence of one or more of PIK3CA gene amplification; a mutation in PIK3CA; and a decrease in PTEN protein expression; and treating a patient that is positive for the presence of one or more of PIK3CA gene amplification; a mutation in PIK3CA; and a decrease in PTEN protein expression by administering an pan-ErbB inhibitor and which further comprise administering one or more compositions or therapies to the subject if the subject is positive for PIK3CA gene amplification wherein the compositions or therapies are useful for treating breast cancer.
  • the additional treatment can comprise one or more of surgery, radiation or additional chemotherapy agents selected from one or more of the following: aromatase inhibitors, including letrozole (Femara), anastrazole (Arimidex), fulvestrant (Faslodex) and exemestane (Aromasin); goserelin (Zoladex); anthracyclines, including doxorubicin (Adriamycin), epirubicin (Ellence), and liposomal doxorubicin (Doxil); taxanes, including docetaxel (Taxotere), paclitaxel (Taxol), and protein-bound paclitaxel (Abraxane), Cyclophosphamide (Cytoxan); Capecitabine (Xeloda) and 5 fluorouracil (5 FU); Vinorelbine (Navelbine); Gemcitabine (Gemzar);Trastuzumab (Herceptin), lapatin
  • the invention provides methods for treating breast cancer in a subject which comprise obtaining a sample from the subject; detecting the presence or absence of one or more of PIK3CA gene amplification; a mutation in PIK3CA; and a decrease in PTEN protein expression; and treating a patient that is negative for all three of these biomarkers with Trastuzumab.
  • the invention provides methods of treating a breast cancer subject which comprise detecting the presence or absence of one or more of PIK3CA gene amplification; a mutation in PIK3CA; and a decrease in PTEN protein expression; wherein if a subject is negative for PIK3CA gene amplification; a mutation in PIK3CA; and a decrease in PTEN protein expression the subject is administered Trastuzumab.
  • the invention provides methods for determining if a subject with breast cancer is a candidate for treatment with a pan-ErbB tyrosine kinase inhibitor which comprises: obtaining a sample from the subject; detecting the presence or absence of PIK3CA gene amplification; wherein if the subject is positive for the presence of one or more of the following: PIK3CA gene amplification; a mutation in PIK3CA; and a decrease in PTEN protein expression, then the subject is a identified as a candidate for treatment with a pan-ErbB tyrosine kinase inhibitor.
  • the pan-ErbB inhibitor is irreversible and prevents binding of PIK3CA to the intracellular portion of the ErbB receptor and in some embodiments the intracellular inhibitor of ErbB receptor tyrosine kinases is neratinib.
  • the methods for determining if a subject is a candidate for treatment with a pan-ErbB tyrosine kinase inhibitor or e.g., neratinib comprise detecting a mutation in the PIK3CA gene is selected from the following point mutations: in exon 9 E is substituted with K at position 542 of the protein sequence; in exon 9 is substituted with E with K or D at amino acid 545; and in exon 20 H is substituted with R at amino acid 1047.
  • methods for determining if a subject is a candidate for treatment with a pan-ErbB tyrosine kinase inhibitor or e.g., neratinib comprise the detection of the mutation in the PIK3CA gene comprises a Polymerase Chain Reaction (PCR) assay, direct sequencing of the PIK3CA gene; sequencing of a cDNA generating from a sample in the patient.
  • PCR Polymerase Chain Reaction
  • methods for determining if a subject is a candidate for treatment with a pan-ErbB tyrosine kinase inhibitor or e.g., neratinib comprise the detection of PTEN expression by one or more of: reverse phase protein array, western blotting, semi-quantitative or quantitative IHC.
  • the disclosure provides assays to determine pathway activation using combined approaches genetic, genomic, and protein biomarkers to accurately characterize "PI3K activated" tumors.
  • Such a combined approach to pathway status can be assessed using a statistical stratification of patients in a randomized trial into “pathway on” and “pathway off' subsets to compare the treatment effect in each arm.
  • determining the pathway on versus pathway off status can help select a treatment protocol for a patient suffering from breast cancer.
  • the treatment protocol selected comprises administering neratinib to a breast cancer patient.
  • this strategy discloses the use of a collection of biomarkers to identify a specific "pathway on" patient population that will have clinical benefit from administration of a particular therapeutic pathway inhibitor.
  • a more recent development in patient selection is the identification of drug resistance mechanisms in an effort to distinguish those patients who will achieve clinical benefit from a specific agent from those who will not (e.g., V-Ki-ras2 Kirsten rat sarcoma [KRAS] mutation status identifies those patients who will not benefit from the addition of antibody-based epidermal growth factor receptor (EGFR) inhibitors in colon cancer (1 )
  • EGFR epidermal growth factor receptor
  • PI3K is one of several signaling cascades engaged by the oncogenic RTK complexes at the membrane and may represent a key therapeutic target (recently reviewed in (5).
  • the critical role of this signaling node in cancer is highlighted by the proportion of human malignancies with genetic lesions in genes encoding the components of the cascade, namely PIK3CA, PTEN, PDK1, and AKT.
  • ErbB pathway inhibitors e.g., trastuzumab, lapatinib, neratinib, BIBW2992J, PI3K inhibitors (e.g., XL147, PX-866), mTOR inhibitors (e.g., temsirolimus, everolimus), and dual PI3K-mTOR inhibitors (e.g., BEZ235).
  • the activation of the PI3K pathway has been associated with resistance to ErbB2-targeted therapy in breast cancer, as well as resistance to cytotoxics.
  • Akt phosphorylation is not an entirely specific marker for this signaling node at PI3K and may not completely capture PI3K activation in all tumor samples (6, 7) and (2) tumor- specific levels of PI P3, the most proximal pathway marker, may pose a challenge in the setting of preserved tissues, where accurate measurement of phosphorylated lipids may be more difficult than that of phosphorylated proteins (8).
  • Novel biomarkers aimed at capturing the underlying biology of pathway activation represent promising approaches to measuring pathway activation.
  • Clinical strategies are being developed to answer questions related to biopsy timing and the feasibility of genomic approaches in clinical development paradigms and will help to answer some of these key question in the near future. Nonetheless, such approaches currently remain challenging to implement in the setting of global phase 3 trials. In this setting, it will be imperative to develop panels of assays that are applicable in preserved tumor specimens and performed globally in a homogeneous manner and under standardized conditions (i.e., good laboratory practice).
  • Biomarker discovery for targeted pathway inhibitors in the preclinical setting can employ several distinct approaches, including (1 ) modeling of drug resistance using panels of xenograft models or cell lines exposed to the drug or (2) modeling of pathway activation after perturbing the pathway in preclinical model systems at the molecular level (e.g., siRNA). Biomarkers derived from such models can be further assessed by measuring pathway markers in human tumor tissues.
  • Class IA phosphatidylinositol-3-kinase is a heterodimeric lipid kinase complex with two subunits, the p1 10a catalytic domain and the p85 regulatory domain.
  • PI3K Upon ligand binding and receptor tyrosine kinase (RTK) autophosphorylation, PI3K is recruited to the cell membrane, binds to the intracellular arm of the RTK, and catalyzes the conversion of phosphatidylinositol (4,5)-diphosphate (PI P2) to phosphatidylinositol (3,4,5)-triphosphate (PIP 3 ).
  • PI3K plays a key role in the regulation of cellular processes, such as proliferation, migration, and apoptosis.
  • Akt/PKB and phosphoinositide-dependent kinase-1 are recruited to the membrane and activated by direct binding to the accumulated pool of PI P3.
  • Active PDK1 propagates signaling via phosphorylation of substrates (Akt/PKB, SGK3).
  • Akt/PKB is phosphorylated by both PDK1 (at site T308) and PDK2/mammalian target of rapamycin (mTOR) C2 (at site S473), leading to full activation of Akt/PKB downstream signaling, which leaves Akt/PKB both upstream and downstream of mTOR (6, 9-1 1 ).
  • the kinase activity of the PI3K complex is opposed by the dual phosphatase known as phosphatase and tensin homologue deleted on chromosome 10 (PTEN), which converts PI P3 to PI P2 and essentially functions as a "check" on the activity of PI3K.
  • PTEN tensin homologue deleted on chromosome 10
  • Neratinib (also called HKI-272) inhibits phosphorylation of the ErbB receptors and downstream substrates; due to this activity in preclinical models, neratinib has been shown to inhibit phosphorylation and activation of the PI3K complex. (See, e.g., WO09/052264 at pages 6-7; US2007/0104721 at paragraphs 7 and 21 ; and U.S. Patent No. 7,399,865).
  • PI3K pathway aberrations are present at diagnosis in a significant percentage of breast cancer patients and data suggest that these represent de novo resistance mechanisms to standard therapy.
  • a novel targeted therapy such as a pan-ErbB inhibitor
  • the concept behind this type of biomarker strategy is to identify a biologic subset of patients that are predicted to be resistant to the standard of care therapy, where the addition or substitution of the novel pathway inhibitor would be expected to have greater therapeutic efficacy by overcoming that resistance mechanism.
  • PI3K pathway activation predicts resistance to trastuzumab (12-15).
  • Biomarkers of PI3K pathway activation that differentiate two patient subsets is used to identify patients predicted to have a response to standard trastuzumab therapy (“PI3K OFF") and those who might require treatment with novel pathway inhibitors (e.g., pan-ErbB inhibitors, in the setting of "PI3K ON") to achieve a clinical response.
  • novel pathway inhibitors e.g., pan-ErbB inhibitors, in the setting of "PI3K ON
  • PI P3 levels at the cell membrane that leads to enhanced downstream signaling.
  • the goal of a biomarker strategy incorporating PI3K activation is to develop a series of assays that will be able to differentiate patients and group them into distinct subsets based on the presence of tumors that are (1 ) driven by or dependent on downstream signaling via PI3K or (2) not dependent on this signaling pathway.
  • the combined assessment of PIK3CA mutations and PTEN loss has demonstrated that PI3K pathway activation is a resistance mechanism to trastuzumab therapy in patients with metastatic ErbB2+ breast cancer (12).
  • the known genetic events observed in primary breast cancer samples in the PIK3CA gene leading to pathway activation are composed of hotspot mutations in exons 9 or 20, gene amplification, or the combination of both.
  • Loss of PTEN has been routinely studied in the clinic using standard IHC approaches, typically with an antibody that recognizes a C-terminal protein epitope caused by mutations that can produce truncated forms of the protein.
  • IHC approaches typically with an antibody that recognizes a C-terminal protein epitope caused by mutations that can produce truncated forms of the protein.
  • Various examples of concordance versus discordance between known genetic loss events and the expression of PTEN via IHC exist in the literature; this can lead to some challenges in the interpretation of the underlying biology (16-17).
  • IHC methods can be qualitative or semiquantitative and differences in interpretation can lead to different results.
  • IHC methods detect all species of the full-length protein (functional or dysfunctional) and "reduced" protein levels may derive from either destabilizing mutations, miRNA expression, or co-expressed stabilizing proteins, whereas a full complement of the PTEN protein can be observed with a point mutation in the phosphatase domain (18-19).
  • neratinib is administered to a subject at a dose between 100 and 500 mg per day, between 200 and 400 mg per day, and at a dose of about 250 mg per day.
  • the invention provides a method of treating breast cancer with neratinib in conjunction with another treatment for breast cancer.
  • Additional treatment or treatments can include surgery, radiation or additional chemotherapy agents selected from one or more of the following: aromatase inhibitors, including letrozole (Femara), anastrazole (Arimidex), fulvestrant (Faslodex) and exemestane (Aromasin); goserelin (Zoladex); anthracyclines, including doxorubicin (Adriamycin), epirubicin (Ellence), and liposomal doxorubicin (Doxil); taxanes, including docetaxel (Taxotere), paclitaxel (Taxol), and protein-bound paclitaxel (Abraxane), Cyclophosphamide (Cytoxan); Capecitabine (Xeloda) and 5 fluorouracil (5 FU); Vinorelbine (Nave
  • “Inhibition” of PI3K activity can be direct, as in via preventing the complex from binding to substrate and or sequestering of the enzyme, or indirect, as in preventing transcription or translation of the PIK3CA gene.
  • inhibition of PI3K activity comprises administering a pan-ErbB tyrosine kinase inhibitor, e.g., neratinib.
  • pan-ErbB tyrosine kinase inhibitor e.g., neratinib.
  • intracellular inhibition of PI3K indicates that the PI3K complex is prevented from activity by direct interference with the PI3K pathway inside the cell, as opposed to an inhibition that occurs via blocking binding or inactivation of a transmembrane cell receptor, e.g., as in inhibition with trastuzumab.
  • treating means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • treatment refers to the act of treating as “treating” is defined immediately above.
  • subject and “patient” are used interchangeably.
  • Quantitative assessment of PTEN protein expression Standard IHC methods are used to stain tumors for PTEN protein expression. Digital images are obtained and OD scores for both normal tissue (e.g. stromal or endothelial cell) PTEN, as well as tumor PTEN compartments are obtained. The sample's PTEN score is calculated as tumor PTEN OD/normal tissue PTEN OD. A range of tumor PTEN scores are presented with slight differences in normal tissue (e.g. stromal) PTEN expression. Normalization allows for correction in staining differences as an internal control. PTEN, phosphatase and tensin homolog deleted on chromosome 10; OD, optical density.
  • PIK3CA gene which encodes the p1 10a subunit of the class PI3K complex
  • PIK3CA gene which encodes the p1 10a subunit of the class PI3K complex
  • mutations in PIK3CA have been observed in approximately one quarter of patients in different cohorts tested (range, 8%-40%). Most mutations in breast cancer have been found to cluster in either the kinase or helical domains in exons 9 and 20 of the PIK3CA gene. These gain-of-function mutations disrupt folding interactions in the p1 10a unit and the interface between the p1 10a and p85 subunits, leading to structural changes in the kinase domain that result in increased enzymatic activity.
  • PI3K signaling activity Both helical and kinase domain mutations in exons 9 and 20 lead to a gain of PI3K signaling activity.
  • Studies in breast cancer patients have shown that PIK3CA mutations in total, or specific groups with exon 9 or 20 mutations, have a negative prognostic value.
  • Helical and kinase domain mutations may have different predictive value as well; exon 9 mutations alone predict enhanced sensitivity to the combination of everolimus and letrozole (vs. letrozole alone) in the neoadjuvant setting.
  • Activating mutations in exons 9 and 20 are measured by allele-specific polymerase chain reaction (PCR).
  • PIK3CA amplification is one of the key mechanisms of PI3K pathway activation in ovarian and endometrial cancers; in these patients, amplification leads to increased gene dosage and increased pathway activity and correlates with resistance to standard therapy and poor prognosis (21 , 22, 25, 26). PIK3CA amplifications are observed with less frequency in breast cancer.
  • FISH fluorescence in situ hybridization
  • the tumor suppressor PTEN is a dual-specificity phosphatase (lipid and protein) that functions as a check (or the "brakes") on the PI3K signaling complex. PTEN mediates the dephosphorylation of PIP3 to PIP2, eliminating the membrane binding site for PDK1 and Akt/PKB and thus antagonizing the activity of PI3K.
  • the PTEN gene (at locus 10q23) is inactivated in a number of human malignancies, including breast, brain, endometrial, kidney, and prostate cancers (29-32) The inactivation of PTEN correlates with disease progression and poor prognosis, suggesting a key role in oncogenesis (16, 33-34).
  • PTEN protein expression As used herein, "positive for the presence of a decrease in PTEN protein expression” means a decrease in PTEN expression levels as compared to non tumorigenic tissue (e.g., non-tumorigenic stromal or endothelial tissue).
  • a sample is obtained from a patient with breast cancer.
  • the sample is analyzed for the presence or absence of one or more of PIK3CA gene amplification; a mutation in PIK3CA; and a decrease in PTEN protein expression.
  • the presence of one or more of these results in the patient being designated as having a tumor that is "PI3K ON.” If a patient is designated as "PI3K ON", then the patient is treated with neratinib.
  • any clinical benefit associated with the neratinib or therapeutic combination can be compared with that seen in the standard of care treatment group.
  • PI3K activation is a marker of resistance to trastuzumab (12, 14, 48)
  • alternative treatments available such as the tyrosine kinase inhibitor class of agents (e.g., the irreversible pan-ErbB inhibitor, neratinib, or the reversible Her1/Her2 inhibitor, lapatinib).
  • Two groups of patients are created within a randomized trial— one group of patients in which PI3K pathway activation is apparent in the tumor sample (i.e., "PI3K ON” or patients with the presence of one or more of these: PIK3CA gene amplification; a mutation in PIK3CA; and a decrease in PTEN protein expression) and another group with no evidence of PI3K activation (i.e., "PI3K OFF” or patients with the absence of all three of these: PIK3CA gene amplification; a mutation in PI K3CA; and a decrease in PTEN protein expression).
  • PI3K ON can be defined as "PIK3CA mutation +" and/or "PIK3CA gene amplification” and/or "PTEN loss” and/or "PTEN low.” Based on preliminary biomarker data obtained prior to the clinical trial (to support its predictability of response), such biomarkers can be considered as exploratory endpoints or as secondary endpoints with stratification. Such a grouping of the patients in a randomized trial could be treated as a separate level of stratification in the trial, with a different null hypothesis than standard geographic or prior treatment group stratifications (where the null hypothesis is that differences exist in the strata). For such a pathway grouping stratification, the null hypothesis would be that no difference exists in the treated group.
  • PI3K ON is “PIK3CA mutant” or “PIK3CA amplified” or "PTEN null” or “PTEN reduced.”
  • PI3K OFF is defined as "PIK3CA wild-type and non-amplified,” and "PTEN normal.”
  • PI3K ON patients are treated with neratinib. The clinical benefit can then be compared between these two populations using linear regression methods.
  • the null hypothesis is that the differential treatment effect in the "PI3K ON” group is the same as the differential treatment effect in the "PI3K OFF” group.
  • pan-ErbB inhibitors may be somewhat effective in patients with tumors defined as "PTEN loss” or “PTEN low,” whereas PI3K inhibitors may have less activity against "PTEN loss” tumors and increased efficacy in tumors harboring PIK3CA mutations or amplifications.
  • Li DM, Sun H (1997) TEP1 encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57:2124-2129.
  • Li DM Sun H (1998) PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 95:15406-1541 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

L'invention concerne des méthodes de traitement du cancer du sein, spécifiquement de cancers résistant à un traitement utilisant un ou plusieurs médicaments connus pour traiter le cancer du sein, et des stratégies de sélection de patient correspondantes qui permettent de prédire une réponse de patient à une thérapie médicamenteuse, lesdites stratégies incluant la détection de la présence ou de l'absence, chez un patient, d'un ou de plusieurs des événements comprenant une amplification du gène PIK3CA, une mutation de PIK3CA et une diminution de l'expression de la protéine PTEN ; et traiter le patient présentant un ou plusieurs desdits événements par l'administration, à celui-ci, d'un inhibiteur de la tyrosine kinase pan-ErbB.
PCT/IB2010/055604 2009-12-11 2010-12-06 Biomarqueurs de la voie de la phosphatidylinotisol-3-kinase WO2011070499A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US13/514,556 US20130189274A1 (en) 2009-12-11 2010-12-06 Phosphatidylinositol-3-kinase pathway biomarkers
CA2783743A CA2783743C (fr) 2009-12-11 2010-12-06 Biomarqueurs de la voie de la phosphatidylinotisol-3-kinase
EP19170821.3A EP3575413A1 (fr) 2009-12-11 2010-12-06 Biomarqueurs de la voie phosphatidylinositol-3-kinase
EP10805335A EP2510121A1 (fr) 2009-12-11 2010-12-06 Biomarqueurs de la voie de la phosphatidylinotisol-3-kinase
US15/099,429 US20160222467A1 (en) 2009-12-11 2016-04-14 Phosphatidylinositol-3-kinase pathway biomarkers
US16/416,083 US20190271047A1 (en) 2009-12-11 2019-05-17 Phosphatidylinositol-3-kinase pathway biomarkers
US17/522,637 US20220170107A1 (en) 2009-12-11 2021-11-09 Phosphatidylinositol-3-kinase pathway biomarkers

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28582109P 2009-12-11 2009-12-11
US61/285,821 2009-12-11
US28787209P 2009-12-18 2009-12-18
US61/287,872 2009-12-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/514,556 A-371-Of-International US20130189274A1 (en) 2009-12-11 2010-12-06 Phosphatidylinositol-3-kinase pathway biomarkers
US15/099,429 Division US20160222467A1 (en) 2009-12-11 2016-04-14 Phosphatidylinositol-3-kinase pathway biomarkers

Publications (1)

Publication Number Publication Date
WO2011070499A1 true WO2011070499A1 (fr) 2011-06-16

Family

ID=43628745

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/055604 WO2011070499A1 (fr) 2009-12-11 2010-12-06 Biomarqueurs de la voie de la phosphatidylinotisol-3-kinase

Country Status (5)

Country Link
US (4) US20130189274A1 (fr)
EP (2) EP3575413A1 (fr)
JP (7) JP2011121944A (fr)
CA (1) CA2783743C (fr)
WO (1) WO2011070499A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013083810A1 (fr) * 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification de non-répondeurs aux inhibiteurs de her2
US9139558B2 (en) 2007-10-17 2015-09-22 Wyeth Llc Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9211264B2 (en) 2009-11-09 2015-12-15 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
US9211291B2 (en) 2009-04-06 2015-12-15 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
CN105274188A (zh) * 2014-05-29 2016-01-27 北京雅康博生物科技有限公司 Pik3ca基因突变检测试剂盒
US9265784B2 (en) 2008-08-04 2016-02-23 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US9511063B2 (en) 2008-06-17 2016-12-06 Wyeth Llc Antineoplastic combinations containing HKI-272 and vinorelbine
US10596162B2 (en) 2005-02-03 2020-03-24 Wyeth Llc Method for treating gefitinib resistant cancer
IT201800010730A1 (it) * 2018-11-30 2020-05-30 Univ Degli Studi Milano Metodo per classificare pazienti affetti da tumore alla mammella idonei per immunoterapia
US10729672B2 (en) 2005-11-04 2020-08-04 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272
EP3695016A4 (fr) * 2017-11-14 2021-07-14 Hanmi Pharm. Co., Ltd. Biomarqueur indiquant une réponse à une thérapie au poziotinib contre le cancer

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140050689A (ko) * 2011-07-28 2014-04-29 제넨테크, 인크. Pik3ca h1047r 녹-인 비인간 동물 유방암 모델
NZ702244A (en) * 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
CA2985894A1 (fr) 2015-05-15 2016-11-24 Memorial Sloan-Kettering Cancer Center Utilisation d'inhibiteurs de phosphoinositide 3-kinase pour le traitement de malformations vasculaires
US9953133B2 (en) 2015-06-03 2018-04-24 General Electric Company Biological data annotation and visualization
US10672505B2 (en) 2015-06-03 2020-06-02 General Electric Company Biological data annotation and visualization
US9607375B2 (en) * 2015-06-03 2017-03-28 Eileen B. Gallagher Biological data annotation and visualization
JP2022500379A (ja) * 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
JP2022519317A (ja) 2019-02-06 2022-03-22 ベンセラ，インコーポレイティド 局所ホスホイノシチド３－キナーゼ阻害剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006098978A1 (fr) * 2005-03-09 2006-09-21 Abbott Laboratories Procede diagnostique d’identification des patients candidats a un traitement au trastuzumab
US20070104721A1 (en) 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP1978106A1 (fr) * 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Amplificateur ayant une protection de sortie, en particulier un amplificateur opérationnel pour une application audio
WO2009052264A2 (fr) 2007-10-17 2009-04-23 Wyeth Sels maléates de (e)-n-{4-[3-chloro-4-(2-pyridinylméthoxy)anilino]-3-cyano-7-éthoxy-6-quinolinyl}-4-(diméthylamino)-2-buténamide et leurs formes cristallines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1899463A4 (fr) * 2005-05-09 2009-11-25 Ariad Pharma Inc Biomarqueurs permettant d'évaluer la probabilité selon laquelle une tumeur est sensible à un inhibiteur de mtor
ES2529790T3 (es) * 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
WO2006098978A1 (fr) * 2005-03-09 2006-09-21 Abbott Laboratories Procede diagnostique d’identification des patients candidats a un traitement au trastuzumab
US20070104721A1 (en) 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272
EP1978106A1 (fr) * 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Amplificateur ayant une protection de sortie, en particulier un amplificateur opérationnel pour une application audio
WO2009052264A2 (fr) 2007-10-17 2009-04-23 Wyeth Sels maléates de (e)-n-{4-[3-chloro-4-(2-pyridinylméthoxy)anilino]-3-cyano-7-éthoxy-6-quinolinyl}-4-(diméthylamino)-2-buténamide et leurs formes cristallines

Non-Patent Citations (54)

* Cited by examiner, † Cited by third party
Title
ADELAIDE J; FINETTI P; BEKHOUCHE I ET AL.: "Integrated profiling of basal and luminal breast cancers", CANCER RES, vol. 67, 2007, pages 11565 - 11575
ALI IU; SCHRIML LM; DEAN M: "Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity", J NATL CANCER INST, vol. 91, 1999, pages 1922 - 1932
ALLEGRA CJ; JESSUP JM; SOMERFIELD MR ET AL.: "American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy", J CLIN ONCOL, vol. 27, 2009, pages 2091 - 2096
BEDARD PL; CARDOSO F; PICCART-GEBHART MJ: "Stemming resistance to HER-2 targeted therapy", J MAMMARY GLAND BIOL NEOPLASIA, vol. 14, 2009, pages 55 - 66
BERNS K ET AL., CANCER CELL, vol. 12, no. 4, October 2007 (2007-10-01), pages 395 - 402
BERNS K; HORLINGS HM; HENNESSY BT ET AL.: "A functional genetic approach identifies the P13K pathway as a major determinant of trastuzumab resistance in breast cancer", CANCER CELL, vol. 12, 2007, pages 395 - 402
BERNS KATRIEN ET AL: "A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer", CANCER CELL, CELL PRESS, US, vol. 12, no. 4, 16 October 2007 (2007-10-16), pages 395 - 402, XP002592491, ISSN: 1535-6108, [retrieved on 20071015], DOI: DOI:10.1016/J.CCR.2007.08.030 *
BETTENDORF O; SCHMIDT H; STAEBLER A ET AL.: "Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate", GENES CHROMOSOMES CANCER, vol. 47, 2008, pages 565 - 572
BLANCO-APARICIO C; RENNER O; LEAL JF ET AL.: "PTEN, more than the AKT pathway", CARCINOGENESIS, vol. 28, 2007, pages 1379 - 1386
BOARD RE; THELWELL NJ; RAVETTO PF ET AL.: "Multiplexed assays for detection of mutations in PIK3CA", CLIN CHEM, vol. 54, 2008, pages 757 - 760
BOSE S; CRANE A; HIBSHOOSH H ET AL.: "Reduced expression of PTEN correlates with breast cancer progression", HUM PATHOL, vol. 33, 2002, pages 405 - 409
BOSE S; WANG SI; TERRY MB ET AL.: "Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas", ONCOGENE, vol. 17, 1998, pages 123 - 127
BUERGER H; PACKEISEN J; BOECKER A ET AL.: "Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study", J PATHOL, vol. 203, 2004, pages 545 - 550
DEPOWSKI PL; ROSENTHAL SI; ROSS JS: "Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer", MOD PATHOL, vol. 14, 2001, pages 672 - 676
EICHHORN PJ; GILI M; SCALTRITI M ET AL.: "Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235", CANCER RES, vol. 68, 2008, pages 9221 - 9230
ELLIS MATTHEW J ET AL: "PIKing the Winner for Phosphatidylinositol 3-Kinase Inhibitors in ErbB2-Positive Breast Cancer: Let's Not PTENed It's Easy!", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 19, 1 October 2007 (2007-10-01), pages 5661 - 5662, XP008104382, ISSN: 1078-0432, DOI: DOI:10.1158/1078-0432.CCR-07-1698 *
ENGELMAN JA: "Targeting P13K signalling in cancer: opportunities, challenges and limitations", NAT REV CANCER, vol. 9, 2009, pages 550 - 562
GARCIA JM; SILVA J; PENA C ET AL.: "Promoter methylation of the PTEN gene is a common molecular change in breast cancer", GENES CHROMOSOMES CANCER, vol. 41, 2004, pages 117 - 124
GUERTIN DA; STEVENS DM; THOREEN CC ET AL.: "Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1", DEV CELL, vol. 11, 2006, pages 859 - 871
HUANG TH; WU F; LOEB GB ET AL.: "Upregulation of miR-21 by HER2/neu signaling promotes cell invasion", J BIOL CHEM., 2009
HYNES NE; LANE HA: "ERBB receptors and cancer: the complexity of targeted inhibitors", NAT REV CANCER, vol. 5, 2005, pages 341 - 354
LI DM; SUN H: "PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells", PROC NATL ACAD SCI USA, vol. 95, 1998, pages 15406 - 15411
LI DM; SUN H: "TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta", CANCER RES, vol. 57, 1997, pages 2124 - 2129
LI J; YEN C; LIAW D ET AL.: "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.[see comment]", SCIENCE, vol. 275, 1997, pages 1943 - 1947
LU Y; LIN YZ; LAPUSHIN R ET AL.: "The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells", ONCOGENE, vol. 18, 1999, pages 7034 - 7045
MA YY; WEI SJ; LIN YC ET AL.: "PIK3CA as an oncoqene in cervical cancer", ONCOGENE, vol. 19, 2000, pages 2739 - 2744
MAEHAMA T: "PTEN: its deregulation and tumorigenesis", BIOL PHARM BULL, vol. 30, 2007, pages 1624 - 1627
MAEHAMA T; TAYLOR GS; DIXON JE: "PTEN and myotubularin: novel phosphoinositide phosphatases", ANNU REV BIOCHEM, vol. 70, 2001, pages 247 - 279
MAEHAMA T; TAYLOR GS; SLAMA JT ET AL.: "A sensitive assay for phosphoinositide phosphatases", ANAL BIOCHEM, vol. 279, 2000, pages 248 - 250
MENG F; HENSON R; WEHBE-JANEK H ET AL.: "MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer", GASTROENTEROLOGY, vol. 133, 2007, pages 647 - 658
NAGATA Y; LAN KH; ZHOU X ET AL.: "PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.[see comment]", CANCER CELL, vol. 6, 2004, pages 117 - 127
O'BRIEN N ET AL.: "Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib", MOL CANCER THER, vol. 9, no. 6, 2010, pages 1489 - 1502
PEREZ-TENORIO G; ALKHORI L; OLSSON B ET AL.: "PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer", CLIN CANCER RES, vol. 13, 2007, pages 3577 - 3584
PERREN A; WENG LP; BOAG AH ET AL.: "Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast", AM J PATHOL, vol. 155, 1999, pages 1253 - 1260
REDON R; MULLER D; CAULEE K ET AL.: "A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains", CANCER RES, vol. 61, 2001, pages 4122 - 4129
RUBIN MA; GERSTEIN A; REID K ET AL.: "10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,NO) prostate cancer", HUM PATHOL, vol. 31, 2000, pages 504 - 508
SAAL LH; HOLM K; MAURER M ET AL.: "PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma", CANCER RES, vol. 65, 2005, pages 2554 - 2559
SALVESEN HB; CARTER SL; MANNELQVIST M ET AL.: "Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of P13 kinase activation", PROC NATL ACAD SCI USA, vol. 106, 2009, pages 4834 - 4839
SAMUELS Y; ERICSON K: "Oncogenic P13K and its role in cancer", CURR OPIN ONCOL, vol. 18, 2006, pages 77 - 82
SHAYESTEH L; LU Y; KUO WL ET AL.: "PIK3CA is implicated as an oncogene in ovarian cancer", NAT GENET, vol. 21, 1999, pages 99 - 102
STECK PA; PERSHOUSE MA; JASSER SA ET AL.: "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers", NATURE GENETICS, vol. 15, 1997, pages 356 - 362
STEMKE-HALE K; GONZALEZ-ANGULO AM; LLUCH A ET AL.: "An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer", CANCER RES, vol. 68, 2008, pages 6084 - 6091
STOKOE D; STEPHENS LR; COPELAND T ET AL.: "Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B", SCIENCE, vol. 277, 1997, pages 567 - 570
VASUDEVAN KM; BARBIE DA; DAVIES MA ET AL.: "AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer", CANCER CELL, vol. 16, 2009, pages 21 - 32
WOENCKHAUS J; STEGER K; STURM K ET AL.: "Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer", VIRCHOWS ARCH, vol. 450, 2007, pages 387 - 395
WONG K-K ET AL: "A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 15, no. 7, 1 April 2009 (2009-04-01), pages 2552 - 2558, XP002591681, ISSN: 1078-0432, [retrieved on 20090324], DOI: DOI:10.1158/1078-0432.CCR-08-1978 *
WU G; MAMBO E; GUO Z ET AL.: "Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors", J CLIN ENDOCRINOL METAB, vol. 90, 2005, pages 4688 - 4693
WU G; XING M; MAMBO E ET AL.: "Somatic mutation and gain of copy number of PIK3CA in human breast cancer", BREAST CANCER RES, vol. 7, 2005, pages R609 - 616
WU GUOJUN ET AL: "Somatic mutation and gain of copy number of PIK3CA in human breast cancer", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 7, no. 5, 31 May 2005 (2005-05-31), pages R609 - R616, XP021011863, ISSN: 1465-5411, DOI: DOI:10.1186/BCR1262 *
YANG H; KONG W; HE L ET AL.: "MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN", CANCER RESEARCH, vol. 68, 2008, pages 425 - 433
YIM EK; PENG G; DAI H ET AL.: "Rak functions as a tumor suppressor by regulating PTEN protein stability and function", CANCER CELL, vol. 15, 2009, pages 304 - 314
YUAN TL; CANTLEY LC: "P13K pathway alterations in cancer: variations on a theme", ONCOGENE, vol. 27, 2008, pages 5497 - 5510
ZHOU J; WULFKUHLE J; ZHANG H ET AL.: "Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance", PROC NATL ACAD SCI USA, vol. 104, 2007, pages 16158 - 16163
ZHOU Q; CHEUNG YB; JADA SR ET AL.: "EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues", CANCER BIOL THER, vol. 5, 2006, pages 1445 - 1449

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596162B2 (en) 2005-02-03 2020-03-24 Wyeth Llc Method for treating gefitinib resistant cancer
US10603314B2 (en) 2005-02-03 2020-03-31 The General Hospital Corporation Method for treating gefitinib resistant cancer
US10729672B2 (en) 2005-11-04 2020-08-04 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272
US9630946B2 (en) 2007-10-17 2017-04-25 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US10035788B2 (en) 2007-10-17 2018-07-31 Wyeth Llc Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9139558B2 (en) 2007-10-17 2015-09-22 Wyeth Llc Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9511063B2 (en) 2008-06-17 2016-12-06 Wyeth Llc Antineoplastic combinations containing HKI-272 and vinorelbine
US10111868B2 (en) 2008-06-17 2018-10-30 Wyeth Llc Antineoplastic combinations containing HKI-272 and vinorelbine
US9265784B2 (en) 2008-08-04 2016-02-23 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US9211291B2 (en) 2009-04-06 2015-12-15 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
US9211264B2 (en) 2009-11-09 2015-12-15 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
WO2013083810A1 (fr) * 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification de non-répondeurs aux inhibiteurs de her2
CN105274188A (zh) * 2014-05-29 2016-01-27 北京雅康博生物科技有限公司 Pik3ca基因突变检测试剂盒
EP3695016A4 (fr) * 2017-11-14 2021-07-14 Hanmi Pharm. Co., Ltd. Biomarqueur indiquant une réponse à une thérapie au poziotinib contre le cancer
IT201800010730A1 (it) * 2018-11-30 2020-05-30 Univ Degli Studi Milano Metodo per classificare pazienti affetti da tumore alla mammella idonei per immunoterapia

Also Published As

Publication number Publication date
CA2783743A1 (fr) 2011-06-16
JP2016169229A (ja) 2016-09-23
JP2022022296A (ja) 2022-02-03
JP2017101072A (ja) 2017-06-08
CA2783743C (fr) 2022-10-04
JP2019052187A (ja) 2019-04-04
US20190271047A1 (en) 2019-09-05
JP2020169212A (ja) 2020-10-15
US20130189274A1 (en) 2013-07-25
JP2015110669A (ja) 2015-06-18
US20220170107A1 (en) 2022-06-02
EP3575413A1 (fr) 2019-12-04
US20160222467A1 (en) 2016-08-04
EP2510121A1 (fr) 2012-10-17
JP2011121944A (ja) 2011-06-23

Similar Documents

Publication Publication Date Title
US20220170107A1 (en) Phosphatidylinositol-3-kinase pathway biomarkers
Di Nicolantonio et al. Precision oncology in metastatic colorectal cancer—from biology to medicine
Kim et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
Remon et al. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins
CN102216775B (zh) 对hsp90-抑制剂的易感性
Corless et al. Gastrointestinal stromal tumours: origin and molecular oncology
Coughlin et al. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy
SG194800A1 (en) Biomarkers for hedgehog inhibitor therapy
McGowan et al. PIK3CA mutations as prognostic factor in squamous cell lung carcinoma
Yamawaki et al. Integrative analyses of gene expression and chemosensitivity of patient-derived ovarian cancer spheroids link G6PD-driven redox metabolism to cisplatin chemoresistance
Quattrone et al. Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors
Schirripa et al. Biomarker-driven and molecular targeted therapies for colorectal cancers
Jour et al. Genomic and transcriptomic analyses of NF1-mutant melanoma identify potential targeted approach for treatment
US9903867B2 (en) Methods for predicting and improving the survival of colorectal cancer patients
Sequist et al. LUX-Lung 3: a randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations (subgroup analysis)
US20140187537A1 (en) Methods of predicting outcomes of chemotherapy treatments and alternative therapies
Howell Lung Cancer Cells Survive EGFR TKI Exposure Through Upregulation of Cholesterol Synthesis
Li Molecular Alterations that Take Roles in Gastric Tumorigenesis and Metastasis
WO2024102649A1 (fr) Utilisation de l'état de la cycline e1 en tant que biomarqueur prédictif pour traitement du cancer avec inhibiteurs de wee1
Stewart Modeling targeted therapy mechanisms and predictive biomarker discovery using human primary non-small cell lung cancer xenografts
Adelaiye-Ogala Epigenetic Alterations Associated with Resistance to Anti-VEGF Receptors in Advanced Clear Cell Renal Cell Carcinoma
Kim et al. KIF5B-RET Fusion gene may coincide oncogenic mutations of or gene EGFR KRAS in lung adenocarcinomas.
Wong Overcoming primary and acquired erlotinib resistance with epidermal growth factor receptor (EGFR) and phosphoinositide 3-kinase (PI3K) co-inhibition in pancreatic cancer
Quattrone Selected genes involved in GIST evolution from indolent to advanced tumours
Triscott Polo-like kinase 1 as a prognostic and therapeutic target in high-grade brain tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10805335

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 13514556

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2783743

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010805335

Country of ref document: EP